Here are five things to know:
• The stock has a 1 (strong buy) rating from Zacks Investment
• 12-month consensus target prices is $21
• Earnings per share are expected at $0.33 for the quarter
• K2M traded down 2.38 percent on Monday
• Trading volume is at 142,914
At the beginning of January, Piper Jaffray began coverage on K2M shares and set an “overweight” rating at $25 price target.
More articles on orthopedic devices:
Spine device company stock report: 5 key companies—Feb. 26
Globus Medical acquires device manufacturer—5 key notes
Invuity raises $20M in financing round
